Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vital signs alert could save lives in blood cancer care

NCT ID NCT06409767

Disease control Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether using a simple early warning score (NEWS) to quickly move high-risk blood cancer patients to the ICU can reduce deaths and organ failure. Over 2,200 adults receiving intensive chemotherapy or stem cell transplants will take part across ten hospitals. Half the hospitals will use the warning system; the other half will continue usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
National Early Warning Score (NEWS) monitoring with ICU referral
What this could lead to
If it works, this could show that closely monitoring vital signs and acting early saves more lives in blood cancer patients undergoing intensive treatment.
What could go wrong
This is a large trial but it tests a monitoring strategy, not a new drug. The benefit may be small, and early ICU admission could increase anxiety and resource use without improving survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,224 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient * Hospitalization in a protected unit of a hematology department for induction therapy of acute myeloid leukemia or acute lymphoblastic leukemia induction, intensive chemotherapy with autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation * Expected length of stay in the hematology department of at least 7 days * Patient with social security * Signed informed consent form Exclusion Criteria: * Decision of care limitation with decision not to transfer to ICU or not initiate organ support * Pregnant, parturient or breastfeeding woman * Person deprived of liberty by judicial or administrative decision * Person under forced psychiatric care * Person under legal protection * Person unable to express consent * Hospitalization for Chimeric Antigenic Receptor (CAR) T-cell therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia leukemia lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leukemia Lymphoma Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Amiens-Picardie

    RECRUITING

    Amiens, 80054, France

  • Centre Hospitalier Universitaire Besancon

    RECRUITING

    Besançon, 25030, France

  • Centre Hospitalier Universitaire Brest

    RECRUITING

    Brest, 29609, France

  • Centre Hospitalier Universitaire Nantes

    RECRUITING

    Nantes, 44093, France

  • Centre Hospitalier Universitaire d'Angers

    RECRUITING

    Angers, 49933, France

  • Centre Hospitalier Universitaire poitiers

    RECRUITING

    Poitiers, 86021, France

  • Centre Hospitalier universitaire Nancy

    RECRUITING

    Nancy, 45011, France

  • centre Hospitalier Universitaire Saint etienne

    RECRUITING

    Saint-Etienne, 42270, France

  • centre Hospitalier Universitaire Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 67098, France

  • centre Hospitalier Universitaire Tours

    RECRUITING

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.